Pharmaceutical composition comprising an immunoglobulin Fc region as a carrier
Disclosed is a novel use of an immunoglobulin Fc fragment, and more particularly, a pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier. The pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier remarkably extends the serum half-life of a drug while maintaining the in vivo activity of the drug at relatively high levels. Also, when the drug is a polypeptide drug, the pharmaceutical composition has less risk of inducing immune responses compared to a fusion protein of the immunoglobulin Fc fragment and a target protein, and is thus useful for developing long-acting formulations of various polypeptide drugs.
1. A pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier, wherein said immunoglobulin Fc fragment does not contain the variable regions of the heavy and light chains of the immunoglobulin, and is covalently linked to a drug that is a physiologically active polypeptide through a non-peptide linker.
2. The pharmaceutical composition according to claim 1 , wherein the immunoglobulin Fc fragment is aglycosylated.
3. The pharmaceutical composition according to claim 1 , wherein the immunoglobulin Fc fragment is composed of one to four domains selected from the group consisting of C H 1, C H 2, C H 3 and C H 4 domains.
4. The pharmaceutical composition according to claim 3 , wherein the immunoglobulin Fc fragment further includes a hinge region.
5. The pharmaceutical composition according to claim 1 , wherein the immunoglobulin Fc fragment is selected from the group consisting of Fc fragments from IgG, IgA, IgD, IgE, IgM, and combinations and hybrids thereof.
6. The pharmaceutical composition according to claim 5 , wherein the immunoglobulin Fc fragment is selected from the group consisting of Fc fragments from IgG1, IgG2, IgG3, IgG4, and combinations and hybrids thereof.
7. The pharmaceutical composition according to claim 6 , wherein the immunoglobulin Fc fragment is an IgG4 Fc fragment.
8. The pharmaceutical composition according to claim 7 , wherein the immunoglobulin Fc fragment is a human aglycosylated IgG4 Fc fragment.
9. The pharmaceutical composition according to claim 1 , wherein said non-peptide linker is selected from the group consisting of polyethylene glycol single polymers, polypropylene glycol single polymers, ethylene glycol propylene glycol copolymers, polyoxyethylated polyols, polyvinvyl alcohols, polysaccharides, dextrans, polyvinyl ethyl ethers, biodegradable polymers, lipid polymers, chitins, hyaluronic acids, and combinations thereof.
10. The pharmaceutical composition according to claim 1 , wherein the physiologically active polypeptide is selected from the group consisting of hormones, cytokines, enzymes, antibodies, growth factors, transcription regulatory factors, coagulation factors, vaccines, structural proteins, ligand proteins and receptors.
11. The pharmaceutical composition according to claim 10 , wherein the physiologically active polypeptide is selected from the group consisting of human growth hormone, growth hormone releasing hormone, growth hormone releasing peptide, interferons, interferon receptors, colony stimulating factors, glucagon-like peptides, G-protein-coupled receptor, interleukins, interleukin receptors, enzymes, interleukin binding proteins, cytokine binding proteins, macrophage activating factor, macrophage peptide, B cell factor, T cell factor, protein A, allergy inhibitor, cell necrosis glycoproteins, immunotoxin, lymphotoxin, tumor necrosis factor, tumor suppressors, metastasis growth factor, alpha-1 antitrypsin, albumin, alpha-lactalbumin, apolipoprotein-E, erythropoietin, highly glycosylated erythropoietin, angiopoietins, hemoglobin, thrombin, thrombin receptor activating peptide, thrombomodulin, factor VII, factor VIIa, factor VIII, factor IX, factor XIII, plasminogen activating factor, fibrin-binding peptide, urokinase, streptokinase, hirudin, protein C, C-reactive protein, renin inhibitor, collagenase inhibitor, superoxide dismutase, leptin, platelet-derived growth factor, epithelial growth factor, epidermal growth factor, angiostatin, angiotensin, bone growth factor, bone stimulating protein, calcitonin, insulin, atriopeptin, cartilage inducing factor, elcatonin, connective tissue activating factor, tissue factor pathway inhibitor, follicle stimulating hormone, luteinizing hormone, luteinizing hormone releasing hormone, nerve growth factors, parathyroid hormone, relaxin, secretin, somatomedin, insulin-like growth factor, adrenocortical hormone, glucagon, cholecystokinin, pancreatic polypeptide, gastrin releasing peptide, corticotropin releasing factor, thyroid stimulating hormone, autotaxin, lactoferrin, myostatin, receptors, receptor antagonists, cell surface antigens, virus derived vaccine antigens, monoclonal antibodies, polyclonal antibodies, and antibody fragments.
12. The pharmaceutical composition according to claim 11 , wherein the physiologically active polypeptide is selected from the group consisting of human growth hormone, colony stimulating factor, interferon-alpha, human erythropoietin and Fab′ antibody fragment.
13. The pharmaceutical composition according to claim 9 , wherein said non-peptide linker is a polyethylene glycol single polymer (PEG).